Cargando…
Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma
Autores principales: | Sidana, Surbhi, Hosoya, Hitomi, Jensen, Alexandria, Liu, Lawrence, Goyal, Anmol, Hovanky, Vanna, Sahaf, Bita, Bharadwaj, Sushma, Latchford, Theresa, Arai, Sally, Leahy, Sheryl, Mei, Matthew, Budde, Lihua E., Muffly, Lori S., Frank, Matthew J., Dahiya, Saurabh, Htut, Myo, Miklos, David, Janakiram, Murali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576036/ https://www.ncbi.nlm.nih.gov/pubmed/37833271 http://dx.doi.org/10.1038/s41408-023-00929-0 |
Ejemplares similares
-
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy
por: Fabrizio, Vanessa A., et al.
Publicado: (2022) -
A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL
por: Jain, Nitin, et al.
Publicado: (2016) -
Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/refractory B-ALL patients
por: Ma, Yunju, et al.
Publicado: (2023) -
Fabrizio VA, Boelens JJ, Mauguen A, et al. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Adv. 2022;6(7):1961-1968.
Publicado: (2023) -
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy
por: Ferreri, Christopher J., et al.
Publicado: (2023)